Loading clinical trials...

A Phase III Trial of HRS-1893 in Patients With Obstructive Hypertrophic Cardiomyopathy | Clinical Trials | Clareo Health

RECRUITINGPHASE3

A Phase III Trial of HRS-1893 in Patients With Obstructive Hypertrophic Cardiomyopathy

A Multicentre, Randomized, Double-blind, Placebo-parallel-controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of HRS-1893 Tablets in the Treatment of Obstructive Hypertrophic Cardiomyopathy

NCT07021976•Shandong Suncadia Medicine Co., Ltd.

View on ClinicalTrials.gov

Summary

The study is being conducted to evaluate the efficacy and safety of HRS-1893 for obstructive hypertrophic cardiomyopathy.

Eligibility

Age

18 - 85 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Age 18-85 years old, gender unlimited.
•2. BMI\<35 kg/m2.
•3. The diagnosis was obstructive hypertrophic cardiomyopathy.
•4. Laboratory determination of echocardiography showed that Rest LVOT-G≥50 mmHg, or Rest LVOT-G≥30 mmHg and LVOT-G≥50 mmHg after Valsalva action.
•5. Echocardiographic laboratory tests showed LVEF≥60%.
•6. NYHA classification: Grade II - III.
•7. Understand the study procedure and sign the informed consent in person, willing to strictly follow the clinical study protocol to complete the study.

Exclusion Criteria

•1. Known or suspected invasive, genetic or storage diseases (e.g. Noonan syndrome, Fabre's disease, amyloidosis) that cause cardiac hypertrophy (similar to oHCM).
•2. Had a history of severe valvular heart disease.
•3. Abnormal laboratory test results during screening, or any other clinically significant abnormal screening laboratory values, which are determined by the researcher to be unsuitable for inclusion.
•4. Other circumstances where the researchers consider the subjects unsuitable to participate in this trial, such as physical or mental illnesses or conditions that may increase the risk of the trial, affect the subjects' compliance with the protocol, or affect the subjects' completion of the trial.

Locations (1)

Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College

Beijing, Beijing Municipality, China

Key Dates

Start Date

August 11, 2025

Primary Completion Date

September 1, 2026

Completion Date

November 1, 2026

Last Updated

August 20, 2025

Enrollment

216

ESTIMATED participants

Conditions

Obstructive Hypertrophic Cardiomyopathy

Interventions

HRS-1893 Tablets

DRUG

HRS-1893 Placebo Tablets

DRUG

Contacts

Yun Jin

CONTACT

+86-0518-82342973 yun.jin.yj1@hengrui.com

Effect of Mavacamten Treatment on Coronary Flow Reserve in oHCM

NCT06023186

Obstructive Hypertrophic Cardiomyopathy

View study

NOT_YET_RECRUITINGNA

Efficacy of Mavacamten Combined With Radiofrequency Ablation in Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy

NCT06856265

Obstructive Hypertrophic CardiomyopathyMavacamten+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 20, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Phase III Trial of HRS-1893 in Patients With Obstructive Hypertrophic Cardiomyopathy

Inclusion Criteria

Exclusion Criteria

Effect of Mavacamten Treatment on Coronary Flow Reserve in oHCM

Efficacy of Mavacamten Combined With Radiofrequency Ablation in Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Left Ventricular Mass Index Predicts Clinical Outcomes in Patients with Obstructive Hypertrophic Cardiomyopathy Undergoing Septal Myectomy

A Study to Evaluate the Efficacy and Safety of Mavacamten in Chinese Adults With Symptomatic Obstructive HCM

Feasibility Study of the DragonFire for Hypertrophic Obstructive Cardiomyopathy

Feasibility Study of the DragonFire for Hypertrophic Obstructive Cardiomyopathy